Journal Article
. 2020 Jul;3(7).
doi: 10.1001/jamanetworkopen.2020.7213.

Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer

Dat Nguyen 1 John Yu 2 William C Reinhold 3 Sherry X Yang 1 
  • PMID: 32644137
  •     34 References
  •     3 citations


Importance: It is not well understood whether prognostic factors in breast cancer are affected by specific treatment and vary by clinical outcome type compared with untreated patients.

Objective: To identify independent clinical and molecular measurements associated with overall survival (OS) and recurrence-free survival (RFS) by homogeneous treatment in women with breast cancer.

Design, Setting, And Participants: This prognostic study included 956 patients diagnosed with invasive breast cancer from hospital centers across 4 geographical regions of the United States who participated in the accreditation program of the Commission on Cancer of the American College of Surgeons from 1985 to 1997. The duration of follow-up ranged from 1 to 282 months. The study analysis was conducted from June 10, 2019, to March 18, 2020.

Main Outcomes And Measures: Analysis of OS and RFS in patients who underwent chemotherapy, radiotherapy, or endocrine therapy alone compared with no systemic or locoregional therapy. Cox proportional hazards regression models were used to estimate independent performance and 95% CI of age, tumor size, number of positive nodes (nodal status), tumor grades 2 and 3, p53 status, estrogen receptor (ER) status, and ERBB2 (formerly HER2) status.

Results: Among 956 participants, median age was 61 (range, 25-96) years. Age (adjusted hazard ratio [AHR], 2.24; 95% CI, 1.27-3.94; P = .01) and high grade (AHR, 2.05; 95% CI, 1.09-3.86; P = .02), in addition to nodal status and tumor size, were independently associated with OS and RFS, respectively, in untreated patients. p53 status (AHR, 2.11; 95% CI, 1.07-4.18; P = .03) and ER status (AHR, 0.46; 95% CI, 0.23-0.92; P = .03) were associated with higher and lower risks of death, respectively, whereas nodal status (AHR, 1.13; 95% CI, 1.06-1.20; P < .005), high grade (AHR, 4.01; 95% CI, 1.51-10.70; P = .01), and ERBB2 positivity (AHR, 2.67; 95% CI, 1.25-5.70; P = .01) were associated with the risk of recurrence after endocrine therapy. Tumor size (AHR for OS, 2.76 [95% CI, 1.79-4.31; P < .005]; AHR for RFS, 2.27 [95% CI, 1.23-4.18; P = .01]) and ERBB2 status (AHR for OS, 5.35 [95% CI, 1.31-21.98; P = .02]; AHR for RFS, 6.05 [95% CI, 1.48-24.78; P = .01]) were independently associated with radiotherapy outcomes, and nodal status was significantly associated with chemotherapy outcomes (AHR for OS, 1.06 [95% CI, 1.02-1.09; P < .005]; AHR for RFS, 1.05 [95% CI, 1.01-1.09; P = .01]).

Conclusions And Relevance: In this study, independent prognostic factors were associated with specific treatment and weighted by the outcome category with reference to untreated patients within biological and clinical contexts.

The importance of identifying and validating prognostic factors in oncology.
Susan Halabi, Kouros Owzar.
Semin Oncol, 2010 May 25; 37(2). PMID: 20494694    Free PMC article.
Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators.
E R Fisher, J Costantino, B Fisher, C Redmond.
Cancer, 1993 Mar 15; 71(6 Suppl). PMID: 8443763
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C Wolff, M Elizabeth Hale Hammond, +14 authors, Mitchell Dowsett.
J Clin Oncol, 2018 May 31; 36(20). PMID: 29846122
Highly Cited.
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
F E Harrell, K L Lee, D B Mark.
Stat Med, 1996 Feb 28; 15(4). PMID: 8668867
Highly Cited. Review.
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Mitsugu Yamamoto, Mitsuchika Hosoda, +6 authors, Hiroko Yamashita.
Cancer Sci, 2013 Oct 15; 105(1). PMID: 24118529    Free PMC article.
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Hiroko Yamashita, Mariko Nishio, +4 authors, Hirotaka Iwase.
Breast Cancer Res, 2003 Dec 19; 6(1). PMID: 14680497    Free PMC article.
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, +12 authors, Nikolaus Schultz.
Cancer Discov, 2012 May 17; 2(5). PMID: 22588877    Free PMC article.
Highly Cited.
The Cooperative Breast Cancer Tissue Resource: archival tissue for the investigation of tumor markers.
A G Glass, H Donis-Keller, +5 authors, Cooperative Breast Cancer Tissue Resource.
Clin Cancer Res, 2001 Jul 13; 7(7). PMID: 11448894
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Santhi D Konduri, Rajesh Medisetty, +8 authors, Gokul M Das.
Proc Natl Acad Sci U S A, 2010 Aug 11; 107(34). PMID: 20696891    Free PMC article.
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Hyman B Muss, Mei-Yin C Polley, +25 authors, Lisa Carey.
J Clin Oncol, 2019 Jul 25; 37(26). PMID: 31339827    Free PMC article.
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
Julia Foldi, Tess O'Meara, +3 authors, Lajos Pusztai.
J Clin Oncol, 2019 Apr 04; 37(16). PMID: 30943126
Surfing the p53 network.
B Vogelstein, D Lane, A J Levine.
Nature, 2000 Dec 01; 408(6810). PMID: 11099028
Highly Cited.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
Suparna Bonthala Wedam, Jennifer A Low, +17 authors, Sandra M Swain.
J Clin Oncol, 2006 Jan 05; 24(5). PMID: 16391297
Highly Cited.
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
Sherry X Yang, Seth M Steinberg, Dat Nguyen, Sandra M Swain.
Int J Oncol, 2011 Mar 15; 38(5). PMID: 21399868    Free PMC article.
Systematic review and meta-analysis of the efficacy of breast conservation therapy followed by radiotherapy in four breast cancer subtypes.
Xin-Bin Pan, Rou-Jun Chen, +2 authors, Xiao-Dong Zhu.
Oncotarget, 2017 Sep 17; 8(34). PMID: 28915682    Free PMC article.
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Bishal Gyawali, Spencer Phillips Hey, Aaron S Kesselheim.
JAMA Netw Open, 2019 Jan 16; 1(2). PMID: 30646078    Free PMC article.
Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
Sherry X Yang, Eric C Polley.
Breast Cancer Res Treat, 2019 Feb 13; 175(2). PMID: 30746635    Free PMC article.
Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
William F Anderson, Bingshu E Chen, Ismail Jatoi, Philip S Rosenberg.
Breast Cancer Res Treat, 2006 May 11; 100(1). PMID: 16685588
REporting recommendations for tumor MARKer prognostic studies (REMARK).
Lisa M McShane, Douglas G Altman, +4 authors, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics.
Breast Cancer Res Treat, 2006 Aug 26; 100(2). PMID: 16932852
Highly Cited.
Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, +25 authors, Fabrice André.
Nature, 2019 May 24; 569(7757). PMID: 31118521
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
Sherry X Yang, Joseph P Costantino, +7 authors, Sandra M Swain.
J Clin Oncol, 2010 May 19; 28(18). PMID: 20479407    Free PMC article.
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
Alan S Coates, Ewan K A Millar, +10 authors, Robert L Sutherland.
Breast Cancer Res, 2012 Nov 07; 14(6). PMID: 23127292    Free PMC article.
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.
P D Pharoah, N E Day, C Caldas.
Br J Cancer, 1999 Sep 02; 80(12). PMID: 10471047    Free PMC article.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Sherry X Yang, Eric Polley, Stanley Lipkowitz.
Cancer Treat Rev, 2016 Mar 21; 45. PMID: 26995633    Free PMC article.
Highly Cited. Review.
Estrogen receptor prevents p53-dependent apoptosis in breast cancer.
Shannon T Bailey, Hyunjin Shin, +2 authors, Myles Brown.
Proc Natl Acad Sci U S A, 2012 Oct 19; 109(44). PMID: 23077249    Free PMC article.
Loss of function and p53 protein stabilization.
M V Blagosklonny.
Oncogene, 1997 Nov 19; 15(16). PMID: 9365234
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
Hiroko Yamashita, Tatsuya Toyama, +6 authors, Hirotaka Iwase.
Breast Cancer Res, 2006 Jul 28; 8(4). PMID: 16869955    Free PMC article.
Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer.
JAMA, 2019 Jan 23; 321(3). PMID: 30667505
Highly Cited. Review.
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
William J Gradishar, Benjamin O Anderson, +30 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2017 Apr 14; 15(4). PMID: 28404755
Highly Cited.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer.
Sherry X Yang, Eric C Polley, Dat Nguyen.
Theranostics, 2017 Apr 07; 7(4). PMID: 28382166    Free PMC article.
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
Andrei Fodor, Chiara Brombin, +24 authors, N G Di Muzio.
Breast, 2020 Dec 17; 55. PMID: 33326894    Free PMC article.
Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
Isabella Cristina Santos Soares, Marcelo Adeodato Bello, Anke Bergmann, Luiz Claudio Santos Thuler.
Breast Cancer Res Treat, 2021 Jan 09;. PMID: 33417086
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial.
Renaud Sabatier, Jean-Yves Pierga, +6 authors, Anthony Gonçalves.
Cancers (Basel), 2021 Jan 21; 13(1). PMID: 33466225    Free PMC article.